✦ LIBER ✦

Treatment of multiple sclerosis with an anti–interleukin-2 receptor monoclonal antibody

✍ Scribed by John W. Rose; Hilary E. Watt; Andrea T. White; Noel G. Carlson

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 97 KB
Volume: 56
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.20287

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Humanized monoclonal anti–interleukin-6

Humanized monoclonal anti–interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease

✍ Masahiro Iwamoto; Hiroyuki Nara; Daisuke Hirata; Seiji Minota; Norihiro Nishimot 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB

Successful treatment of reactive arthrit

Successful treatment of reactive arthritis with a humanized antiâinterleukin-6 receptor antibody, tocilizumab

✍ Tanaka, Toshio ;Kuwahara, Yusuke ;Shima, Yoshihito ;Hirano, Toru ;Kawai, Mari ;O 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB

Role of interleukin-6 in a patient with

Role of interleukin-6 in a patient with tumor necrosis factor receptor–associated periodic syndrome: Assessment of outcomes following treatment with the anti–interleukin-6 receptor monoclonal antibody tocilizumab

✍ Prashantha M. Vaitla; Paul M. Radford; Patrick J. Tighe; Richard J. Powell; Eliz 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 1 views

Successful treatment of a patient with t

Successful treatment of a patient with takayasu arteritis using a humanized anti–interleukin-6 receptor antibody

✍ Norihiro Nishimoto; Hideko Nakahara; Naoko Yoshio-Hoshino; Toru Mima 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Treatment of rheumatoid arthritis with h

Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial

✍ Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Sh 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 2 views

## Abstract ## Objective Interleukin‐6 (IL‐6) is a pleiotropic cytokine that regulates the immune response, inflammation, and hematopoiesis. Overproduction of IL‐6 plays pathologic roles in rheumatoid arthritis (RA), and the blockade of IL‐6 may be therapeutically effective for the disease. This s

Therapeutic benefit of blocking interleu

Therapeutic benefit of blocking interleukin-6 activity with an anti–interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial

✍ E. H. S. Choy; D. A. Isenberg; T. Garrood; S. Farrow; Y. Ioannou; H. Bird; N. Ch 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB